SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

• Bank of America Securities Health Care Conference (Las Vegas, Nevada)
  • Tuesday, May 13, 2025, at 2:20 p.m. PT, corporate presentation

• H.C. Wainwright 3rd Annual BioConnect Investor Conference (New York, New York)
  • Tuesday, May 20, 2025, at 12:00 p.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
This email address is being protected from spambots. You need JavaScript enabled to view it.

Argot Partners (media)
David Rosen
646-461-6387
This email address is being protected from spambots. You need JavaScript enabled to view it.

Argot Partners (investors)
Laura Perry
212-600-1902
This email address is being protected from spambots. You need JavaScript enabled to view it.